Back to results
US 12,514,912 B2Granted
Compositions comprising three OspA fusion proteins for medical use
AssigneesValneva Austria GmbH, Pfizer Inc.
InventorsNicole Bézay, Romana Hochreiter, Urban Lundberg, Steven Russell Bailey, Annaliesa Sybil Anderson, Kathrin Ute Jansen, Daniel Alfred Scott
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipS1D1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
Claims24
A method of eliciting an immune response in a human adult or human child against Lyme disease, comprising administering a composition comprising:
- (a) a first fusion protein comprising the amino acid sequence of SEQ ID NO:
- 1 (Lip-S1D1-S2D1), (b) a second fusion protein comprising the amino acid sequence of SEQ ID NO:
- 2 (Lip-S4D1-S3hybD1), and (c) a third fusion protein comprising the amino acid sequence of SEQ ID NO:
- 3 (Lip-S5D1-S6D1):
- (i) to a human adult or a human child at least two times or at least three times, wherein each dose of the composition comprises a total protein content of the three fusion proteins of 120 to 200 μg;
- or
- (ii) to a human child at least two times or at least three times, wherein each dose of the composition comprises a total protein content of the three fusion proteins of 60 to 100 μg,
- wherein the composition comprises the first, second, and third fusion proteins at a 1:1:1 weight ratio.
5 more elements
Dependencies are inferred from the claim text.